Evidence map›Paper›PMID 29263880›Full record

ArticleNPJ vaccines2017

Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Margherita Coccia, Catherine Collignon, Caroline Hervé, Aurélie Chalon, Iain Welsby, Sophie Detienne, Mary J van Helden, Sheetij Dutta, Christopher J Genito, Norman C Waters and 11 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07527247 (Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity), which is not on this map. Cited by 173 papers.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 240 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Unconventional functions of natural killer cells in homeostasis and disease.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Margherita CocciaGSK Vaccines, Rixensart, Belgium.
Catherine CollignonGSK Vaccines, Rixensart, Belgium.
Caroline HervéGSK Vaccines, Rixensart, Belgium.
Aurélie ChalonGSK Vaccines, Rixensart, Belgium.
Iain WelsbyInstitute for Medical Immunology, Université libre de Bruxelles, Gosselies, Belgium.
Sophie DetienneInstitute for Medical Immunology, Université libre de Bruxelles, Gosselies, Belgium.
Mary J van HeldenVlaams Instituut voor Biotechnologie, Inflammation Research Center, Ghent University, Ghent, Belgium.
Sheetij DuttaMalaria Vaccine Branch, Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland USA.
Christopher J GenitoMalaria Vaccine Branch, Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland USA.
Norman C WatersMalaria Vaccine Branch, Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland USA.
Katrijn Van DeunDepartment of Methodology and Statistics, Tilburg University, Tilburg, The Netherlands.
Age K SmildeBiosystems data analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
Robert A van den BergGSK Vaccines, Rixensart, Belgium.
David FrancoGSK Vaccines, Rixensart, Belgium.
Patricia BourguignonGSK Vaccines, Rixensart, Belgium.
Sandra MorelGSK Vaccines, Rixensart, Belgium.
Nathalie GarçonGSK Vaccines, Rixensart, Belgium.
Bart N LambrechtVlaams Instituut voor Biotechnologie, Inflammation Research Center, Ghent University, Ghent, Belgium.
Stanislas GorielyInstitute for Medical Immunology, Université libre de Bruxelles, Gosselies, Belgium.
Robbert van der MostGSK Vaccines, Rixensart, Belgium.
Arnaud M DidierlaurentGSK Vaccines, Rixensart, Belgium.
GlaxoSmithKline (Belgium) · BEUniversité Libre de Bruxelles · BEWalter Reed Army Institute of Research · USGhent University · BEKU Leuven · BEUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining immunostimulants in adjuvants can improve the quality of the immune response to vaccines. Here, we report a unique mechanism of molecular and cellular synergy between a TLR4 ligand, 3-

Identifiers

PMID29263880
PMCPMC5627273
OpenAlexW2737108166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.